Skip to navigation Skip to content

Treating SPMS

Share

Modifying the Disease Course

More than a dozen disease modifying therapies are approved by the U.S. Food and Drug Administration (FDA) for use in relapsing forms of MS. This includes individuals who have active secondary-progressive MS, meaning they continue to have inflammatory demyelination (new lesions on MRI) and clinical relapses. Individuals who have been on one of these medications during the initial relapsing-remitting phase of the disease will likely continue on it unless it is no longer adequately controlling their disease activity.

Mavenclad®, an oral therapy, is FDA approved for relapsing forms of MS including active secondary progressive MS.

Mayzent®, an oral therapy, is FDA approved for relapsing forms of MS including active secondary progressive MS.

Novantrone® is FDA-approved for people with worsening relapsing-remitting MS (worsening in between relapses) and those with secondary progressive MS (started with relapses but are now worsening with no or few relapses).  This DMT is used infrequently due to serious side effects and risks.

Read more about these therapies in The MS Disease-Modifying Medications (.pdf).

Read more about starting, stopping or switching medications in the American Academy of Neurology Guideline: Disease Modifying Therapies for Adults with Multiple Sclerosis.

Managing symptoms

Regardless of the course of MS a person is experiencing, proactive symptom management is essential to maintaining comfort and productivity, and enhancing quality of life.

Rehabilitation

Rehabilitation specialists have an important role from the time of diagnosis helping people function optimally in spite of their MS, including enhancing mobility and promoting safety and independence.

Share